Bright Minds Biosciences (DRUG) stays a Strong Buy after Phase 2 BMB-101 seizure-reduction data; see 2026 catalysts, ...

BrightMinds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ('Bright Minds” or the 'Company”) today closed its recently announced ...

Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...

Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ('Bright Minds” or the 'Company”) announces the launch of a public ...

BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...

Bright Minds Biosciences ( ($TSE:DRUG) ) has issued an update. On January 5, 2026, Bright Minds Biosciences announced plans to report topline ...

On Monday, Microchip said it now expects third-quarter fiscal 2026 net sales of approximately $1.185 billion for the period ...

Biosciences announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating ...

Shares of Bright Minds Biosciences rose after the company released positive topline results from its phase two trial of a treatment for patients with drug-resistant Absence Seizures and Developmental ...

Bright Minds Biosciences (NASDAQ:DRUG) stock rose 5% after the clinical-stage biotechnology company announced positive topline results from its Phase 2 BREAKTHROU ...

With a variety of proposals to further restrict abortion access in South Carolina on the table, which bills have the most ...

Sourya Dipta Ghosh is a young, bright-eyed filmmaker, quite literally travelling with his first feature film Before I Forget You. Nervous and very polite, Sourya Dipta talked to The Statesman about ...